World’s Best Journal in Medicine Publishes on Phase II Llama Antibodies

16/02/2016 - 3 minutes

Ablynx, the llama antibody biotech in Belgium, has now proven to be on solid ground regarding their orphan drug for a rare blood disease. Now the New England Journal of Medicine has published their phase II results.

ablynx_titan_hercules_thrombocytopenia_purpura_NEJM_alpaca_antibodiesAblynx often makes our biotech headlines, be it with the curious science of their nanobody platform or with their partnerships with big pharma companies.

Despite being actively developing therapies in partnerships with big pharma for different diseases (including multiple sclerosis with Genzyme, cancer with MSD,  and with NovoNordisk in a yet undisclosed disease), their flagship is a drug for the rare acquired thrombotic thrombocytopenic purpura (aTTP).

This blood disorder is an autoimmune disease which afflicts only about 5 people in a million per year, but can lead to severe complications (like brain damage and kidney failure). It is currently treated with a daily plasma exchange (TPE) – a sort of blood “cleaning”, that requires people to stay in the hospital for long periods of time,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member